摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Methyl 2-methyl-4-(1,3-thiazol-2-yl)pyrazole-3-carboxylate

中文名称
——
中文别名
——
英文名称
Methyl 2-methyl-4-(1,3-thiazol-2-yl)pyrazole-3-carboxylate
英文别名
methyl 2-methyl-4-(1,3-thiazol-2-yl)pyrazole-3-carboxylate
Methyl 2-methyl-4-(1,3-thiazol-2-yl)pyrazole-3-carboxylate化学式
CAS
——
化学式
C9H9N3O2S
mdl
——
分子量
223.25
InChiKey
WQTCMQVXCCZRAP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.1
  • 重原子数:
    15
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.22
  • 拓扑面积:
    85.2
  • 氢给体数:
    0
  • 氢受体数:
    5

文献信息

  • NOVEL PYRAZOLE DERIVATIVE
    申请人:MOCHIDA PHARMACEUTICAL CO., LTD.
    公开号:US20140378447A1
    公开(公告)日:2014-12-25
    It has been desired to develop a pharmaceutical composition, which is used in agents for preventing and/or treating various diseases related to PDE10 (e.g. mental disorder and neurodegenerative disorder). The present invention provides: compounds having PDE10 inhibitory effect, in particular, compounds having a 4-heteroarylpyrazole-5-carboxylic acid amide structure represented by the following formula (I), or their pharmaceutically acceptable salts, or their solvates; pharmaceutical compositions comprising, as active ingredients, the compounds, or their pharmaceutically acceptable salts, or their solvates; and medical use of the compounds, or their pharmaceutically acceptable salts, or their solvates.
    已经有人希望开发一种药物组合物,用于预防和/或治疗与PDE10相关的各种疾病(例如精神障碍和神经退行性疾病)。本发明提供:具有PDE10抑制作用的化合物,特别是具有以下式(I)所代表的4-杂环芳基吡唑-5-羧酰胺结构的化合物,或其药学上可接受的盐,或其溶剂化物;包含作为活性成分的化合物,或其药学上可接受的盐,或其溶剂化物的药物组合物;以及化合物的医学用途,或其药学上可接受的盐,或其溶剂化物。
  • Carboxamide, Sulfonamide and Amine Compounds and Methods for Using Them
    申请人:Rigel Pharmaceuticals, Inc.
    公开号:US20140378429A1
    公开(公告)日:2014-12-25
    The disclosure relates particularly to certain carboxamide, sulfonamide and amine compounds and pharmaceutical compositions thereof, and to methods of treating and ameliorating disorders and conditions related to the adiponectin pathway, sphingolipid metabolism, oxidative stress, mitochondrial dysfunction, free radical damage and metabolic inefficiency, among others. In certain embodiments, the compounds have the structures (I-1), (2-I) and (3-I) (The chemical formulas should be inserted here) in which the variables are as described herein.
    本公开涉及特定的羧酰胺、磺酰胺和胺化合物及其制药组合物,以及治疗和改善与脂联素途径、鞘脂代谢、氧化应激、线粒体功能障碍、自由基损伤和代谢效率等相关的疾病和病症的方法。在某些实施例中,化合物具有结构(I-1)、(2-I)和(3-I)(化学式应在此处插入),其中变量如本文所述。
  • US8980888B2
    申请人:——
    公开号:US8980888B2
    公开(公告)日:2015-03-17
  • US8980889B2
    申请人:——
    公开号:US8980889B2
    公开(公告)日:2015-03-17
  • US9440970B2
    申请人:——
    公开号:US9440970B2
    公开(公告)日:2016-09-13
查看更多